Coronary Heart Disease (CHD) — A Biorepository for Coronary Heart Disease in Qatar
Citation(s)
Cooper RS, Psaty BM Should ethnicity serve as the basis for clinical trial design? Diversity and inclusiveness should remain the guiding principles for clinical trials. Circulation. 2005 Dec 6;112(23):3660-5; discussion 3665-6.
Cortese DA A vision of individualized medicine in the context of global health. Clin Pharmacol Ther. 2007 Nov;82(5):491-3.
Ding K, Kullo IJ Genome-wide association studies for atherosclerotic vascular disease and its risk factors. Circ Cardiovasc Genet. 2009 Feb;2(1):63-72. doi: 10.1161/CIRCGENETICS.108.816751. Review.
Evans BJ, Meslin EM Encouraging translational research through harmonization of FDA and common rule informed consent requirements for research with banked specimens. J Leg Med. 2006 Jun;27(2):119-66.
Ginsburg GS, Burke TW, Febbo P Centralized biorepositories for genetic and genomic research. JAMA. 2008 Mar 19;299(11):1359-61. doi: 10.1001/jama.299.11.1359.
Khoja T, Rawaf S, Qidwai W, Rawaf D, Nanji K, Hamad A Health Care in Gulf Cooperation Council Countries: A Review of Challenges and Opportunities. Cureus. 2017 Aug 21;9(8):e1586. doi: 10.7759/cureus.1586. Review.
Khoury MJ, Jones K, Grosse SD Quantifying the health benefits of genetic tests: the importance of a population perspective. Genet Med. 2006 Mar;8(3):191-5. Review.
Kullo IJ, Ballantyne CM Conditional risk factors for atherosclerosis. Mayo Clin Proc. 2005 Feb;80(2):219-30. Review.
Kullo IJ, Cooper LT Early identification of cardiovascular risk using genomics and proteomics. Nat Rev Cardiol. 2010 Jun;7(6):309-17. doi: 10.1038/nrcardio.2010.53. Epub 2010 May 4. Review.
Kullo IJ, Fan J, Pathak J, Savova GK, Ali Z, Chute CG Leveraging informatics for genetic studies: use of the electronic medical record to enable a genome-wide association study of peripheral arterial disease. J Am Med Inform Assoc. 2010 Sep-Oct;17(5):568-74. doi: 10.1136/jamia.2010.004366.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
